doi: 10.1038/nm0310-241.
Rare opportunities appear on the horizon to treat rare diseases
- PMID: 20208483
- DOI: 10.1038/nm0310-241
Item in Clipboard
Rare opportunities appear on the horizon to treat rare diseases
Nat Med.
2010 Mar.
No abstract available
Similar articles
-
Rare diseases, orphan drugs, and orphaned patients.Mol Interv. 2006 Aug;6(4):186-91. doi: 10.1124/mi.6.4.2. Mol Interv. 2006. PMID: 16960139 No abstract available.
-
Adopting orphan drugs--two dozen years of treating rare diseases.N Engl J Med. 2006 Feb 2;354(5):445-7. doi: 10.1056/NEJMp058317. N Engl J Med. 2006. PMID: 16452556 No abstract available.
-
Orphan drugs and orphan tests in the USA.Community Genet. 2004;7(4):169-72. doi: 10.1159/000082255. Community Genet. 2004. PMID: 15692190 No abstract available.
-
The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.Clin Pharmacol Ther. 2010 Oct;88(4):449-53. doi: 10.1038/clpt.2010.193. Clin Pharmacol Ther. 2010. PMID: 20856241 Review.
-
Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.Discov Med. 2011 Apr;11(59):367-75. Discov Med. 2011. PMID: 21524390 Review.
Cited by
-
Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.Nanomedicine (Lond). 2019 Jan;14(1):93-126. doi: 10.2217/nnm-2018-0120. Epub 2018 Nov 19. Nanomedicine (Lond). 2019. PMID: 30451076 Free PMC article. Review.
-
Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.Orphanet J Rare Dis. 2017 Aug 23;12(1):143. doi: 10.1186/s13023-017-0690-5. Orphanet J Rare Dis. 2017. PMID: 28835285 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
